Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746914004488/a2218453z10-k.htm
Exhibit 99.1
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Contact: Bryan J. Carey President and CFO 239-931-7285 BCarey@rtsx.com |
|
Investors: Nick Laudico The Ruth Group 646-536-7030 nlaudico@theruthgroup.com |
21ST CENTURY ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS
Fourth Quarter 2013 Highlights:
· Total company pro forma revenues of $209.2 million, up 23.9% year-over-year, including $5.8 million in pro forma contribution from acquisitions; excluding acquisitions, revenues grew 20.5% year-over-year
· Total domestic Radiation Oncology cases completed increased 12.3%
· Domestic same market treatments per day increased 7.9%
· International cases increased 7.0%
· Pro Forma Adjusted EBITDA of $27.2 million
· Completed acquisition of OnCure Holdings, Inc. (Oncure) on October 25, adding significant scale and opportunity for long term revenue growth and operating synergies
· Transitioned corporate identity to 21st Century Oncology brand, recognized globally for high quality integrated cancer care (ICC) services
· Acquired strategically located radiation therapy facility with certificate of need (CON) in Roanoke Rapids, NC; upgrading with advanced technologies and clinical pathways
· Entered strategic partnership with ProHealth Care Associates, LLP, the largest physician group practice in the metropolitan New York area, to operate an ICC practice in Riverhead, NY as well as jointly pursue additional strategic opportunities
Full Year 2013 Highlights:
· Total company pro forma revenues of $845.3 million, up 20.7% year-over-year, including $108.8 million in pro forma contribution from acquisitions; excluding acquisitions, revenues grew 6.1% year-over-year
· Total domestic Radiation Oncology cases completed increased 13.1%
· Domestic same market treatments per day increased 4.3%
· International cases increased 5.7%
· Pro Forma Adjusted EBITDA of $118.6 million
FORT MYERS, FL, February, 19, 2014 21st Century Oncology Holdings, Inc. (21st Century Oncology, 21C or the Company), the leading global, physician-led provider of
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746914004488/a2218453z10-k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 21St Century Oncology Holdings, Inc..
21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
21St Century Oncology Holdings, Inc. provided additional information to their SEC Filing as exhibits
Ticker: RTSX
CIK: 1503518
Form Type: 10-K Annual Report
Accession Number: 0001047469-14-004488
Submitted to the SEC: Thu May 01 2014 8:53:47 AM EST
Accepted by the SEC: Thu May 01 2014
Period: Tuesday, December 31, 2013
Industry: Offices And Clinics Of Doctors Of Medicine